- Conditions
- Kidney Transplantation, Chronic Kidney Failure
- Interventions
- Cyclosporine (CsA), Belatacept LI (less intensive), Belatacept MI (more intensive)
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 738 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2015
- U.S. locations
- 34
- States / cities
- Birmingham, Alabama • Loma Linda, California • Los Angeles, California + 29 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 386
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Kidney Transplantation
- Interventions
- Arm 1: SOC (mTOR + CNI), Arm 2A: TRACT/MONO mTOR, Arm 2B: TRACT/MONO CNI
- Drug · Biological
- Lead sponsor
- Singulera Therapeutics Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 3
- States / cities
- Phoenix, Arizona • Chicago, Illinois • Rochester, Minnesota
- Conditions
- Kidney Transplant
- Interventions
- Living ACTS website, Standard transplant education procedures
- Behavioral
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 416 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- End Stage Renal Disease (ESRD)
- Interventions
- Not listed
- Lead sponsor
- Phraxis, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 2
- States / cities
- Orangeburg, South Carolina • Spartanburg, South Carolina
- Conditions
- Cardiovascular Diseases, End Stage Renal Disease, Kidney Transplantation, Dialysis Related Complication
- Interventions
- No screening, Regular Screening
- Other
- Lead sponsor
- University of British Columbia
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 3,306 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2028
- U.S. locations
- 2
- States / cities
- Tucson, Arizona • Washington D.C., District of Columbia
- Conditions
- End Stage Kidney Disease
- Interventions
- Website Intervention
- Behavioral
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 123 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2015
- U.S. locations
- 2
- States / cities
- Davis, California • Chicago, Illinois
- Conditions
- Chronic Allograft Nephropathy, Chronic Kidney Disease, Chronic Renal Failure, Disordered Mineral Metabolism, End Stage Renal Disease, Hyperparathyroidism, Hypophosphatemia, Kidney Disease, Kidney Transplantation, Post Renal Transplantation
- Interventions
- Cinacalcet, Placebo
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 114 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 15
- States / cities
- Phoenix, Arizona • Tempe, Arizona • San Francisco, California + 12 more
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Atypical Chronic Myeloid Leukemia, Breakpoint Cluster Region-abl Translocation (BCR-ABL) Negative, Blastic Phase Chronic Myelogenous Leukemia, Childhood Acute Lymphoblastic Leukemia in Remission, Childhood Acute Myeloid Leukemia in Remission, Childhood Chronic Myelogenous Leukemia, Childhood Myelodysplastic Syndromes, Chronic Eosinophilic Leukemia, Chronic Myelomonocytic Leukemia, Chronic Neutrophilic Leukemia, Chronic Phase Chronic Myelogenous Leukemia, de Novo Myelodysplastic Syndromes, Disseminated Neuroblastoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Gastrointestinal Complications, Juvenile Myelomonocytic Leukemia, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Nodal Marginal Zone B-cell Lymphoma, Noncontiguous Stage II Adult Burkitt Lymphoma, Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma, Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma, Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma, Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma, Noncontiguous Stage II Adult Lymphoblastic Lymphoma, Noncontiguous Stage II Grade 1 Follicular Lymphoma, Noncontiguous Stage II Grade 2 Follicular Lymphoma, Noncontiguous Stage II Grade 3 Follicular Lymphoma, Noncontiguous Stage II Mantle Cell Lymphoma, Noncontiguous Stage II Marginal Zone Lymphoma, Noncontiguous Stage II Small Lymphocytic Lymphoma, Poor Prognosis Metastatic Gestational Trophoblastic Tumor, Previously Treated Childhood Rhabdomyosarcoma, Primary Myelofibrosis, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Large Cell Lymphoma, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent Childhood Rhabdomyosarcoma, Recurrent Childhood Small Noncleaved Cell Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Malignant Testicular Germ Cell Tumor, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Neuroblastoma, Recurrent Ovarian Epithelial Cancer, Recurrent Ovarian Germ Cell Tumor, Recurrent Small Lymphocytic Lymphoma, Recurrent Wilms Tumor and Other Childhood Kidney Tumors, Recurrent/Refractory Childhood Hodgkin Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Hairy Cell Leukemia, Relapsing Chronic Myelogenous Leukemia, Secondary Acute Myeloid Leukemia, Secondary Myelodysplastic Syndromes, Splenic Marginal Zone Lymphoma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage II Ovarian Epithelial Cancer, Stage III Adult Burkitt Lymphoma, Stage III Adult Diffuse Large Cell Lymphoma, Stage III Adult Diffuse Mixed Cell Lymphoma, Stage III Adult Diffuse Small Cleaved Cell Lymphoma, Stage III Adult Hodgkin Lymphoma, Stage III Adult Immunoblastic Large Cell Lymphoma, Stage III Adult Lymphoblastic Lymphoma, Stage III Chronic Lymphocytic Leukemia, Stage III Grade 1 Follicular Lymphoma, Stage III Grade 2 Follicular Lymphoma, Stage III Grade 3 Follicular Lymphoma, Stage III Malignant Testicular Germ Cell Tumor, Stage III Mantle Cell Lymphoma, Stage III Marginal Zone Lymphoma, Stage III Multiple Myeloma, Stage III Ovarian Epithelial Cancer, Stage III Small Lymphocytic Lymphoma, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Adult Burkitt Lymphoma, Stage IV Adult Diffuse Large Cell Lymphoma, Stage IV Adult Diffuse Mixed Cell Lymphoma, Stage IV Adult Diffuse Small Cleaved Cell Lymphoma, Stage IV Adult Hodgkin Lymphoma, Stage IV Adult Immunoblastic Large Cell Lymphoma, Stage IV Adult Lymphoblastic Lymphoma, Stage IV Breast Cancer, Stage IV Chronic Lymphocytic Leukemia, Stage IV Grade 1 Follicular Lymphoma, Stage IV Grade 2 Follicular Lymphoma, Stage IV Grade 3 Follicular Lymphoma, Stage IV Mantle Cell Lymphoma, Stage IV Marginal Zone Lymphoma, Stage IV Ovarian Epithelial Cancer, Stage IV Small Lymphocytic Lymphoma
- Interventions
- lithium carbonate, laboratory biomarker analysis
- Drug · Other
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2015
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- End Stage Chronic Renal Failure, Chronic Kidney Disease (Stages 4 and 5), Kidney Transplantation Recipients
- Interventions
- 10˚C deceased donor kidney storage using Traferox XPort
- Device
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Depression, ESRD
- Interventions
- Not listed
- Lead sponsor
- Portland VA Medical Center
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 350 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2010
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Chronic Kidney Diseases, Kidney Transplant
- Interventions
- Allogeneic, vertebral bone marrow-derived mesenchymal stem cells (MSC)
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2031
- U.S. locations
- 1
- States / cities
- Jacksonville, Florida
- Conditions
- Kidney Failure, Chronic, Diabetic Nephropathies, Glomerulonephritis, IGA, Hypertension, Renal
- Interventions
- mycophenolate mofetil (CellCept)
- Drug
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Delayed Graft Function
- Interventions
- Epoetin Alfa
- Drug
- Lead sponsor
- West Penn Allegheny Health System
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 76 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Stenosis of Vascular Prosthetic Devices, Implants and Grafts
- Interventions
- FLAIR Endovascular Stent Graft, PTA
- Device · Procedure
- Lead sponsor
- C. R. Bard
- Industry
- Eligibility
- 21 Years and older
- Enrollment
- 270 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2013
- U.S. locations
- 1
- States / cities
- Bamberg, South Carolina
- Conditions
- Chronic Kidney Diseases, Heart Transplant
- Interventions
- Conversion from IR Tacrolimus to XR Tacrolimus
- Drug
- Lead sponsor
- Loyola University
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Maywood, Illinois
- Conditions
- End-Stage Renal Disease, Living Donors
- Interventions
- Anti-Thymocyte Globulin vs Campath-1H vs Daclizumab
- Drug
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 14 Years and older
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Kidney Failure, Chronic, Peritoneal Dialysis Complication, Transplantation, Healthy
- Interventions
- biopsy sampling
- Procedure
- Lead sponsor
- Heidelberg University
- Other
- Eligibility
- 1 Day to 90 Years
- Enrollment
- 500 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2028
- U.S. locations
- 3
- States / cities
- Birmingham, Alabama • Kansas City, Missouri • Narberth, Pennsylvania
- Conditions
- Delayed Graft Function
- Interventions
- Envarsus XR, Tacrolimus
- Drug
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Kidney Transplant Recipients, Old Age
- Interventions
- Conversion to extended-release tacrolimus, Maintenance of immediate-release tacrolimus
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 92 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Thrombotic Microangiopathies, Atypical Hemolytic Uremic Syndrome, Multiple Organ Dysfunction Syndrome
- Interventions
- Eculizumab
- Drug
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Other
- Eligibility
- Not listed
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 3
- States / cities
- Los Angeles, California • Cincinnati, Ohio • Philadelphia, Pennsylvania
- Conditions
- Weight Loss, Lifestyle Factors
- Interventions
- Wrist activity tracker and scale, Nutritional Coaching group sessions
- Device · Behavioral
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Type 1 Diabetes Mellitus, Hypoglycemia, Labile Diabetes, End-stage Renal Disease
- Interventions
- Allogeneic islets of Langerhans
- Biological
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 18 Years to 70 Years
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Kidney Failure, Chronic
- Interventions
- Not listed
- Lead sponsor
- National Institutes of Health Clinical Center (CC)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 113 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2019
- U.S. locations
- 2
- States / cities
- Washington D.C., District of Columbia • Bethesda, Maryland
- Conditions
- End-stage Renal Disease, Kidney Failure, Chronic
- Interventions
- HAVG
- Biological
- Lead sponsor
- Humacyte, Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 3
- States / cities
- Durham, North Carolina • Houston, Texas • Norfolk, Virginia